Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Device Firms Should Not Ignore Pharma Off-Label Suits, Experts Say

This article was originally published in The Gray Sheet

Executive Summary

While recent case law that appears to give industry more leverage in off-label communications involves drugs, the precedent should apply equally to devices, attorneys say. Nonetheless, companies should be cautious about moving full-steam ahead with off-label promotions


Related Content

BIO Lays Ethical Foundation For Change In Off-Label Communications
Experts Debate Prospects Of Third-Party Agency To Oversee Off-Label Communications
FDA Seeks To Resolve First Amendment Suit By Pacira
Off-Label Pacira Warning Letter Dropped From FDA's Website
Proposed Intended-Use Amendments Invite Questions About FDA's Off-Label Intentions
Vascular Solutions Alleges Misconduct In Off-Label Case
In Case You Missed It: Top 10 "Gray Sheet" Stories In September
Off-Label Promotion Ruling Increases Pressure For FDA Policy Change


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts